Management of cardiovascular complications in systemic lupus erythematosus.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Clinical Rheumatology

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/IJR.09.73PMID 20305727PMCID PMC2839248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between -592A/C polymorphism of interleukin-10 (IL-10) gene and risk of early carotid atherosclerosis.

  2010cited by this paper
• Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study).

  2009cited by this paper
• Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.

  2009cited by this paper
• Antiproteinuric Effect of Angiotensinconverting Enzyme Inhibitors and an Angiotensin II Receptor Blocker in Patients with Lupus Nephritis

  2009cited by this paper
• Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus

  2009cited by this paper
• Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

  2009cited by this paper
• Poor Outcomes After Acute Myocardial Infarction in Systemic Lupus Erythematosus

  2009cited by this paper
• Predictive Value of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a Population-Based Study: The Multi-Ethnic Study of Atherosclerosis

  2009cited by this paper
• Changes in Lipid Profile Between Flare and Remission of Patients with Systemic Lupus Erythematosus: A Prospective Study

  2009cited by this paper
• How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive.

  2009cited by this paper
• 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus.

  2009cited by this paper
• Trials of cardiovascular risk factor management in type 2 diabetes

  2009cited by this paper
• Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.

  2009cited by this paper
• Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement.

  2009cited by this paper
• Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors

  2009cited by this paper
• Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

  2009cited by this paper
• Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease

  2009cited by this paper
• Cardiovascular co-morbidity in early rheumatoid arthritis.

  2009cited by this paper
• Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin

  2009cited by this paper
• Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease

  2009cited by this paper
• Apolipoprotein H Promoter Polymorphisms in Relation to Lupus and Lupus-related Phenotypes

  2009cited by this paper
• Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors

  2009cited by this paper
• Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus

  2009cited by this paper
• Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

  2008cited by this paper
• Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

  2008cited by this paper
• Homocysteine or Renal Impairment: Which Is the Real Cardiovascular Risk Factor?

  2008cited by this paper
• Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.

  2008cited by this paper
• Vascular responsiveness in the microcirculation of patients with systemic lupus erythematosus is not impaired

  2008cited by this paper
• Premature atherosclerotic cardiovascular disease and systemic lupus erythematosus from bedside to bench.

  2008cited by this paper
• Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.

  2008cited by this paper
• The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis.

  2008cited by this paper
• Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

  2008cited by this paper
• Cardiovascular morbidity in psoriatic arthritis

  2008cited by this paper
• Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus.

  2008cited by this paper
• Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

  2008cited by this paper
• Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus

  2008cited by this paper
• Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement.

  2008cited by this paper
• The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus

  2008cited by this paper
• Subclinical carotid atherosclerosis in patients with psoriatic arthritis.

  2008cited by this paper
• Natural antibodies against phosphorylcholine as potential protective factors in SLE.

  2008cited by this paper
• Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort.

  2008cited by this paper
• Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain

  2008cited by this paper
• Cardiovascular disease risk awareness in systemic lupus erythematosus patients.

  2008cited by this paper
• Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus

  2008cited by this paper
• Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA): LXI. Value of C-Reactive Protein as a Marker of Disease Activity and Damage

  2008cited by this paper
• Multiple risk factors for cardiovascular disease and diabetes mellitus.

  2007cited by this paper
• Mycophenolate Mofetil and Atherosclerosis

  2007cited by this paper
• Vitamin D deficiency.

  2007cited by this paper
• Long-term aspirin use and mortality in women.

  2007cited by this paper
• Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.

  2007cited by this paper
• Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA L II): Relationship Between Vascular Events and the Use of Hormone Replacement Therapy in Postmenopausal Women

  2007cited by this paper
• Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus.

  2007cited by this paper
• A pravastatin dose-escalation study in systemic lupus erythematosus

  2007cited by this paper
• Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey.

  2007cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice: executive summary.

  2007cited by this paper
• Cardiovascular disease and modifiable cardiometabolic risk factors.

  2007cited by this paper
• Class of antiretroviral drugs and the risk of myocardial infarction.

  2007cited by this paper
• Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort

  2007cited by this paper
• Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.

  2007cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

  2007cited by this paper
• Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.

  2007cited by this paper
• Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study.

  2007cited by this paper
• Therapy Insight: guidelines for selection of contraception in women with rheumatic diseases

  2007cited by this paper
• Annexin A5 as a Novel Player in Prevention of Atherothrombosis in SLE and in the General Population

  2007cited by this paper
• Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

  2007cited by this paper
• New-onset diabetes and antihypertensive drugs.

  2006cited by this paper
• Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients.

  2006cited by this paper
• Significance of coronary artery calcification score (CACS) for the detection of coronary artery disease (CAD) in chronic dialysis patients.

  2006cited by this paper
• Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis

  2006cited by this paper
• Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated.

  2006cited by this paper
• Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus

  2006cited by this paper
• Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.

  2006cited by this paper
• Assessment of inflammatory markers and endothelial function

  2006cited by this paper
• Vitamin D deficiency in systemic lupus erythematosus.

  2006cited by this paper
• Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus.

  2006cited by this paper
• Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study.

  2006cited by this paper
• Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.

  2006cited by this paper
• Atherogenic Oxidized Low-Density Lipoprotein/β2-Glycoprotein I (oxLDL/β2GPI) Complexes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

  2006cited by this paper
• Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.

  2006cited by this paper
• Angiopoietins: a link between angiogenesis and inflammation.

  2006cited by this paper
• Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri

  2006cited by this paper
• Adipocytokines: mediators linking adipose tissue, inflammation and immunity

  2006cited by this paper
• High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease

  2006cited by this paper
• Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study

  2005cited by this paper
• Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women.

  2005cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Arterial Stiffness in Chronic Inflammatory Diseases

  2005cited by this paper
• Statins: immunomodulators for autoimmune rheumatic disease?

  2005cited by this paper
• Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

  2005cited by this paper
• Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations.

  2005cited by this paper
• Chronic kidney disease: a risk factor for cardiovascular disease.

  2005cited by this paper
• Combined oral contraceptives in women with systemic lupus erythematosus.

  2005cited by this paper
• Premature atherosclerosis in systemic lupus erythematosus.

  2005cited by this paper
• Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.

  2005cited by this paper
• Circulating endothelial progenitor cells and cardiovascular outcomes.

  2005cited by this paper

• Proposal of a novel cardiovascular risk prediction score in lupus nephritis

  2024cites this paper
• Exploring cardiovascular implications in systemic lupus erythematosus: A holistic analysis of complications, diagnostic criteria, and therapeutic modalities, encompassing pharmacological and adjuvant approaches

  2024cites this paper
• Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus

  2024cites this paper
• Predicting the risk of cardiovascular and cerebrovascular event in systemic lupus erythematosus: a Chinese SLE treatment and research group study XXVI

  2024cites this paper
• Prevalence of major adverse cardiovascular events among Saudi patients with systemic lupus erythematosus compared with the general population: updates from the national SLE and PURE cohorts

  2024cites this paper
• Computed Tomography (CT) Calcium Scoring in Primary Prevention of Acute Coronary Syndrome and Future Cardiac Events in Patients With Systemic Lupus Erythematosus

  2023cites this paper
• A Review of Cardiac Manifestations in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome With Focus on Endocarditis

  2022cites this paper
• Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain

  2022cites this paper
• Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up

  2021cites this paper
• Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention

  2021cites this paper
• Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis

  2020cites this paper
• Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases

  2020cites this paper
• The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.

  2020cites this paper
• Management of cardiovascular disease in patients with systemic lupus erythematosus

  2020cites this paper
• Predictors of Quality of Life in Lupus Patients: A Study of Coping, Cognitive Distortions, and Social Support

  2019cites this paper
• Heart rate variability in patients with systemic lupus erythematosus: a systematic review and methodological considerations

  2018cites this paper
• Activation of Peroxisome Proliferator Activator Receptor &bgr;/&dgr; Improves Endothelial Dysfunction and Protects Kidney in Murine Lupus

  2017cites this paper
• Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review

  2017cites this paper
• Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?

  2017cites this paper
• An investigation into the role of endothelial-derived microparticles in an in vitro model of vascular health and disease

  2017cites this paper
• Subclinical left ventricular dysfunction in childhood-onset systemic lupus erythematosus: a two-dimensional speckle-tracking echocardiographic study

  2016cites this paper
• Systemic lupus erythematosus

  2016cites this paper
• The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims

  2015cites this paper
• Obesity and Cytokines in Childhood-Onset Systemic Lupus Erythematosus

  2014influential citation
• Chronic Hydroxychloroquine Improves Endothelial Dysfunction and Protects Kidney in a Mouse Model of Systemic Lupus Erythematosus

  2014cites this paper
• Moving lupus epidemiology forward: returning to the basics

  2014cites this paper
• Systemic Lupus Erythematosus and the Kidney

  2014cites this paper
• Premature Atherosclerotic Cardiovascular Disease in Systemic Lupus Erythematosus: Understanding Management Strategies

  2013influential citation
• Chapter 48 – Systemic Glucocorticoid Therapy in SLE

  2013cites this paper
• Management of women with systemic lupus erythematosus.

  2013cites this paper
• Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus.

  2013cites this paper
• Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus

  2013influential citation
• CARDIOVASCULAR INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

  2012cites this paper
• 274 – Systemic Lupus Erythematosus

  2012cites this paper
• Blood pressure and renal hemodynamic responses to acute angiotension II infusion are enhanced in a female mouse model of systemic lupus erythematosus

  2011cites this paper
• Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.

  2011cites this paper
• Cardiovascular risk assessment in patients with systemic lupus erythematosus: practical aspects

  2011cites this paper
• Integrative and Translational Physiology : Inflammation and Immunity in Organ System Physiology Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus

  2011cites this paper